Orphazyme A/S Return on Equity

Orphazyme A/S's return on equity stands at -3.78%. That is below the Healthcare sector average of 29.39%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Orphazyme A/S sits lower the Healthcare benchmark (29.39%) with a ROE of -3.78%. That is roughly 1386.1% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A ROE of -3.78% for Orphazyme A/S means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how Orphazyme A/S's ROE evolved across reporting periods, while the comparison chart places ORPHY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, ROE is commonly used to spot outliers. Orphazyme A/S's reading of -3.78% (sector avg 29.39%) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.